Skip to main content

Table 3 Changes in brain volumes from baseline in ALZ2002 to the end of the double-blind period in ALZ2004, by treatment group (safety analysis set)

From: Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

DosageRegionPreclinical ADMCI due to AD
Double blind week 24Double blind week 52Double blind week 24Double blind week 52
nMean (SD)nMean (SD)nMean (SD)nMean (SD)
PlaceboTotal hippocampus6− 61.183 (152.8617)4− 192.691 (286.0535)23− 148.955 (110.0055)16− 208.173 (139.2326)
Bilateral ventricles61213.479 (1297.2666)42384.305 (1765.8039)231877.688 (1868.2961)162554.255 (1619.2302)
Whole brain6− 4513.446 (6744.6900)4− 3966.134 (6897.1749)21− 5202.949 (5310.6112)15− 6398.921 (6057.7712)
10 mgTotal hippocampus8− 130.472 (133.3899)4− 314.289 (190.6022)18−130.601 (100.9252)16− 308.766 (198.3581)
Bilateral ventricles81317.472 (1089.6703)43254.365 (1326.9982)181294.812 (1190.6962)163349.908 (2563.2821)
Whole brain8− 7197.703 (7409.7046)4− 17,698.910 (5463.6862)17− 5736.212 (6275.3521)16− 10,815.252 (9814.0704)
25 mgTotal hippocampus5−12.221 (92.4995)5− 129.273 (81.0670)16− 122.374 (86.0882)13− 235.946 (145.2177)
Bilateral ventricles5538.445 (965.7828)51999.089 (1514.6993)161399.116 (1085.9684)132853.589 (1945.9111)
Whole brain5− 1144.502 (7511.2280)5− 4524.925 (6112.8815)14− 6634.464 (5868.5297)13−  9624.766 (8707.2218)
  1. All values are changes in regional volume measured by the boundary shift integral (BSI) method, relative to baseline in ALZ2002; units are cubic millimeters